S. Evans

A phase I trial of AEG35156 (XIAP antisense) administered as a continuous intravenous infusion in patients with advanced tumors.

M. Ranson, T. Ward, C. Dive, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.